What changed
Use of proceeds is trial-specific: ~$4M for INKmune Phase I/II in ovarian cancer, ~$1.5M for INB03 Phase I in advanced cancer with elevated MDSC, ~$2.5M for INB03 Phase II combined with a checkpoint inhibitor.
Risks are the classic clinical-stage stack: no approved products, no product revenue, and a warning that existing cash may only last six months. Trials can be delayed or fail, and regulatory approval is uncertain. Substantial additional capital will be needed.
Context matters here: INMB already trades on Nasdaq. Its lead asset XPro missed the primary cognitive endpoint in the Phase 2 MINDFuL Alzheimer's trial, though a predefined amyloid-positive subgroup showed benefit. Management is pursuing Breakthrough Therapy Designation and an...
Bottom line: this is a small raise funding two early platforms, not a transformational event. The INKmune and INB03 trials are the catalysts to watch, but six months of runway and a recent Alzheimer's miss keep the risk profile high.
Why it matters
Use of proceeds is trial-specific: ~$4M for INKmune Phase I/II in ovarian cancer, ~$1.5M for INB03 Phase I in advanced cancer with elevated MDSC, ~$2.5M for INB03 Phase II combined with a checkpoint i